|Ticker: GSK||Nature of Business: Pharmaceuticals||Location : UK|
|Recent Price: 1,774.74p||52-Week High/Low: 2,726.53p/1,362.80p||Estimated Fair Value: ---|
|Expected Return: ---||Consider Buy: ---||Business Risk: Average|
|Financial Risk: Medium||Economic Moat: Weak||Corporate Governance: Strong|
GlaxoSmithKline Plc, now GSK Plc (GSK), is one of the foremost companies in the world. It was formed from the amalgamation of Glaxo Wellcome Plc and SmithKline Beecham in 2000. The company traces back to 1715 when Plough Court Pharmacy (PCP) was opened in London. PCP was later bought by Glaxo Laboratories Limited. GSK distributes vaccines, medicines and healthcare products. The company, however, has spun off its consumer healthcare business in order to focus on the development, production and marketing of biopharmaceutical products. The consumer healthcare business is a Joint Venture between GSK and Pfizer Inc. The new healthcare company, Haleon Plc, was listed on the London Stock Exchange on 18th July 2022.
Sir Jonathan Symonds retains the board chairmanship he got in September 2019. Dame Emma Walmsley was named chief executive officer of GSK in April 2017. Iain Mackay joined the board as chief financial officer while Dr. Hal Barron doubles as an executive director and chief scientific officer of the company. The board has seven independent non-executive directors, namely Charles Bancroft, Dr. Anne Beal, Dr. Harry Dietz, Dr. Laurie Glimcher, Dr. Jesse Goodman, Urs Rohner and Dr. Vishal Sikka.
In £ Millions